Price
$6.81
Increased by +0.15%
Dollar Volume (20D)
7.29 M
ADR%
4.6
Earnings Report Date (estimate)
Aug 8, 23 (-0.16)
Market Cap.
550.50 M
Shares Float
79.36 M
Shares Outstanding
80.84 M
Beta
0.67
Price / Earnings
-10.64
BPR
0.11
20D Range
6.67 8.39
50D Range
6.67 9.89
200D Range
6.67 11.93
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 8, 23 0.14
Increased by +187.50%
0.17
Decreased by -17.65%
May 9, 23 -0.17
Decreased by -21.43%
-0.18
Increased by +5.56%
Feb 7, 23 -0.17
Decreased by -21.43%
-0.19
Increased by +10.53%
Nov 28, 22 -0.18
Decreased by -20.00%
-0.16
Decreased by -12.50%
Aug 9, 22 -0.16
Decreased by -14.29%
-0.15
Decreased by -6.67%
May 10, 22 -0.14
Decreased by -16.67%
-0.17
Increased by +17.65%
Feb 9, 22 -0.14
Decreased by -16.67%
-0.15
Increased by +6.67%
Nov 24, 21 -0.15
Decreased by -50.00%
-0.15
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 23 0.00
Decreased by N/A%
-11.28 M
Increased by +8.79%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-13.11 M
Decreased by -25.57%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-12.97 M
Decreased by -19.20%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-14.29 M
Decreased by -21.95%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-12.37 M
Decreased by -21.48%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-10.44 M
Decreased by -27.99%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-10.88 M
Decreased by -38.54%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-11.72 M
Decreased by -96.44%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.